Colorectal Cancer Therapeutics Market 2020 | Latest Report Analysis, Key Players, Development, Oppor

The global colorectal cancer therapeutics market size is projected to reach USD 16.58 billion by 2026, owing to the rise in the prevalence of colorectal cancer worldwide. A report by Fortune Business Insights™ titled, "Colorectal Cancer Therapeutics Market Size, Share & Industry Analysis, By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, Others), By Cancer Type (Colorectal Adenocarcinoma, Gastrointestinal Carcinoid Tumors, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026," provides a detailed analysis of the same.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/colorectal-cancer-therapeutics-market-101945

Some of the key colorectal cancer drugs market manufacturers include:

• Novartis AG
• Bayer AG
• Merck Sharp & Dohme Corp.
• Bristol Myers Squibb
• Pfizer Inc.
• Genentech, Inc.
• Ipsen Biopharmaceuticals, Inc.
• Regeneron Pharmaceuticals, Inc.
• Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.)
• Sanofi
• Teva Pharmaceutical Industries Ltd.

According to the report, the colorectal cancer drugs market was valued at USD 9.26 billion in 2018. The forecast period is set from 2019 to 2026, and the market is likely to exhibit a CAGR of 7.6%. As per current colorectal cancer therapeutics market trends, the targeted therapy segment is dominating the market in terms of therapy. This is attributed to the presence of a large number of prominent targeted cancer therapies such as Stivarga, Erbitux, and Avastin.

The report offers a comprehensive overview of the colorectal cancer therapeutics market analysis and its growth trajectories such as drivers, restraints, challenges, and opportunities. Besides that, the report provides a detailed segmentation of the market based on factors such as cancer type, by therapy, distribution channel, and others. It also offers the list of key colorectal cancer drugs market manufacturers and the prime strategies adopted by them to gain a competitive edge in the market.

Request a Sample Copy of Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/colorectal-cancer-therapeutics-market-101945

Launch of Better Therapeutics for Colorectal Cancer to Aid in Expansion of Market

The rise in awareness about colorectal cancer is a major factor driving the colorectal cancer therapeutics market growth. Additionally, the increasing number of corresponding product launches for effective colorectal cancer treatment is further expected to help increase the overall market growth in the forecast period. Moreover, the advent of the latest initiatives aiming to provide effective care of colorectal cancer patients is more likely to aid in the expansion of the market for colorectal cancer drugs. Furthermore, the high mortality rates, coupled with the rising demand for effective cancer therapeutics worldwide, is prognosticated to have a positive effect on the colorectal cancer medications market size in the forthcoming years.

Merck Sharp & Dohme Corp, Genentech, Inc., and Bristol Myers Squibb Holding Leading Market Position

Major vendors in the colorectal cancer therapeutics market are focusing on research and development of novel colorectal cancer therapeutics. Currently, companies such as Bristol Myers Squibb, Genentech, Inc., and Merck Sharp & Dohme Corp are dominating the market. This is owing to the robust pipeline candidates, key strategic decisions, and the presence of a strong oncology portfolio. The overall colorectal cancer therapeutics market is subject to a number of biosimilar launches and has a strong presence of generics, especially for chemotherapy.

Some of the key industry developments in the colorectal cancer therapeutics market are:

July 2019 – Pfizer, a key player in the market for colorectal cancer medications, completed the acquisition of Array BioPharma Inc., for strengthening the oncology pipeline for colorectal cancer treatment.

July 2019 – Allergan and Amgen launched the first anticancer biosimilars Kanjinti and Mvasi, in the U.S. These biosimilars are used for treating colorectal cancer.

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients,